Impact of Zoledronate Gel on the Outcomes of Immediate Dental Implant (Clinical, Radiographic and Biochemical Study)

Aim: The present study was designed to evaluate; the clinical and radiographic effect of topically applied Zoledronate gel on the outcomes of immediate dental implant placement and Biochemical assessment of RANKL level in GCF around dental implant. Subjects and methods: Patients were classified into two groups; group1: Included 9 Patients received immediate dental implant alone. Group 2 Included 9 Patients received immediate dental implant with locally applied zoledronate gel. Modified plaque index (mPI), Modified Bleeding Index (mBI), Pre-implant probing depth (PPD), Implant stability, Biochemical analysis: (RANKL LEVEL) were recorded at base line, 3, 6, 9 and 12 months post-surgically. All patients were evaluated radiographically by CBCT and Standardized periapical radiographs before, after implant placement and after 6 months post-operatively for marginal bone loss. The data were collected, tabulated, computed and statistically analyzed. Results: There was a statistically significant difference between 6 months and 12 months post-operative in modified Bleeding Index, Pre-implant probing depth, marginal bone loss ( p =0.030), ( p =0.036), ( p =0.015) respectively. While there was no significant difference in modified plaque index and Implant stability ( p =0.576). Biochemical analysis: (RANKL LEVEL) There was a statistically significant difference after (3m) between (Group1) and (Group2) where ( p =0.095). Conclusion: From the results the present study, we can conclude that: The use of zoledronate gel at the time of implant placement improves the implant stability, suggesting that might be used as adjunct for initial implant osseintegration. provide successful clinical outcomes (2, 3) and has been documented that this surgical protocol fails to prevent the horizontal and vertical ridge alterations (4) . This may result in impaired esthetics (5) such as marginal soft tissues recessions, especially if treating the buccal side of maxillary sites in patients with a high smile line (6) .